Edition:
United States

Sarepta Therapeutics Inc (SRPT.OQ)

SRPT.OQ on NASDAQ Stock Exchange Global Select Market

79.28USD
10:51am EDT
Change (% chg)

$0.73 (+0.93%)
Prev Close
$78.55
Open
$78.21
Day's High
$80.01
Day's Low
$77.67
Volume
72,237
Avg. Vol
473,781
52-wk High
$84.35
52-wk Low
$28.82

Select another date:

Thu, Apr 5 2018

Sarepta Therapeutics beats bid to revive shareholder class action

A federal appeals court has upheld the dismissal of a lawsuit accusing Sarepta Therapeutics Inc of misleading shareholders by suggesting it had gathered enough data to seek U.S. Food and Drug Administration approval in 2014 to market a treatment for a rare muscle disorder.

BRIEF-Sarepta Therapeutics Announces Plan To Submit A New Drug Application For Accelerated Approval Of Golodirsen

* SAREPTA THERAPEUTICS ANNOUNCES PLAN TO SUBMIT A NEW DRUG APPLICATION (NDA) FOR ACCELERATED APPROVAL OF GOLODIRSEN (SRP-4053) IN PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD) AMENABLE TO SKIPPING EXON 53

BRIEF-Sarepta Therapeutics Reports Q4 Non-GAAP Loss Per Share $0.28

* SAREPTA THERAPEUTICS ANNOUNCES FOURTH QUARTER 2017 AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS

BRIEF-Capital Ventures International Reports 5.4 Pct Passive Stake In Sarepta Therapeutics

* CAPITAL VENTURES INTERNATIONAL REPORTS A 5.4 PERCENT PASSIVE STAKE IN SAREPTA THERAPEUTICS INC AS OF DECEMBER 11, 2017 - SEC FILING Source text: (http://bit.ly/2kzjwV3) Further company coverage:

Sarepta Therapeutics investors seek revival of fraud lawsuit

A lawyer for Sarepta Therapeutics Inc shareholders urged a federal appeals court on Monday to revive a lawsuit claiming the company misled investors about whether it had gathered enough data to seek Food and Drug Administration approval for a treatment for a rare muscle disorder.

Health insurer Anthem eases restrictions on Sarepta's Duchenne treatment

NEW YORK Health insurer Anthem Inc has eased access to Sarepta Therapeutics' treatment for Duchenne muscular dystrophy, and on Thursday changed its reimbursement policy on its website to "medically necessary."

UPDATE 1-Health insurer Anthem eases restrictions on Sarepta's Duchenne treatment

NEW YORK, Nov 9 Health insurer Anthem Inc has eased access to Sarepta Therapeutics' treatment for Duchenne muscular dystrophy, and on Thursday changed its reimbursement policy on its website to "medically necessary."

Health insurer Anthem eases restrictions on Sarepta's Duchenne treatment

NEW YORK, Nov 9 Health insurer Anthem Inc has eased access to Sarepta Therapeutics' treatment for Duchenne muscular dystrophy, and on Thursday changed its reimbursement policy on its website to "medically necessary."

BRIEF-Sarepta Therapeutics announces proposed offering of $375 mln of convertible senior notes

* Sarepta Therapeutics announces proposed offering of $375 million of convertible senior notes due 2024

BRIEF-Sarepta Therapeutics reports FDA clearance of IND for co's ppmo exon 51 candidate, srp-5051

* Sarepta Therapeutics announces FDA clearance of IND for the company's ppmo exon 51 candidate, srp-5051

Select another date: